Stannsoporfin

Summary

Stannsoporfin (CHEMBL4297207) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including metabolic disease and porphyria.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297207
Name	Stannsoporfin
Type	Small molecule
Max phase	3

Also known as: B-992, B992, Estansoporfina, Mesoporphyrin tin, Stanate, Stannsoporfin, Stannsoporfine, Tin mesoporphyrin, STANNSOPORFIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
metabolic disease	3	MONDO:0005066	EFO:0000589
porphyria	2	MONDO:0037939	MONDO:0037939

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE2	6
PHASE1	2
Not specified	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02685137	PHASE3	COMPLETED	Efficacy and Safety of Stannsoporfin in Neonates
NCT00004381	PHASE2	COMPLETED	Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia
NCT00004382	PHASE2	COMPLETED	Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns
NCT00004396	PHASE2	COMPLETED	Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias
NCT00004789	PHASE1/PHASE2	COMPLETED	Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria
NCT00115544	PHASE2	COMPLETED	Safety and Pharmacology of Stanate
NCT00850993	PHASE2	TERMINATED	A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
NCT01887327	PHASE2	COMPLETED	Stannsoporfin With Light Therapy for Newborn Babies With Jaundice
NCT00004397	PHASE1	COMPLETED	Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria
NCT00004398	PHASE1	COMPLETED	Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria
NCT02000830	Not specified	COMPLETED	Follow up Study of Patients Having Participated in Clinical Trial 64,185-204
NCT02033096	Not specified	COMPLETED	Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).